← FDA DRUG APPROVALS

FDA ANDA · ANDA214289

MYCOPHENOLIC ACID

Sponsor: TWI PHARMS

APPLICATION
ANDA214289
TYPE
ANDA
ORIGINAL APPROVAL
2021-11-03
LATEST ACTION
2026-07-29
ROUTE
ORAL
DOSAGE FORM
TABLET, DELAYED RELEASE
MARKETING STATUS
Discontinued

Products

MYCOPHENOLATE SODIUMDiscontinued
MYCOPHENOLATE SODIUM EQ 360MG BASE · TABLET, DELAYED RELEASE · ORAL
MYCOPHENOLATE SODIUMDiscontinued
MYCOPHENOLATE SODIUM EQ 180MG BASE · TABLET, DELAYED RELEASE · ORAL

Approval history

2026-07-29REMS · Supplement 9AP
2024-08-13REMS · Supplement 7AP
2023-01-31Labeling · Supplement 3 · standardAP
2021-11-03UNKNOWN · Original · standard — REMS ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →